Felix Gerhard Maria Dietlein, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorine Radioisotopes | 3 | 2020 | 448 | 1.260 |
Why?
|
Glutamate Carboxypeptidase II | 2 | 2020 | 77 | 0.860 |
Why?
|
Prostatic Neoplasms | 8 | 2021 | 11039 | 0.810 |
Why?
|
Gallium Radioisotopes | 5 | 2021 | 178 | 0.710 |
Why?
|
Oligopeptides | 3 | 2019 | 1176 | 0.660 |
Why?
|
Antigens, Surface | 2 | 2020 | 1663 | 0.640 |
Why?
|
DNA Repair | 4 | 2020 | 2042 | 0.610 |
Why?
|
Niacinamide | 1 | 2019 | 416 | 0.600 |
Why?
|
Urea | 2 | 2016 | 449 | 0.600 |
Why?
|
Nucleotides | 1 | 2020 | 463 | 0.590 |
Why?
|
Lysine | 3 | 2016 | 1008 | 0.530 |
Why?
|
Neoplasms | 9 | 2022 | 21596 | 0.500 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2014 | 117 | 0.460 |
Why?
|
Edetic Acid | 3 | 2019 | 277 | 0.440 |
Why?
|
Organometallic Compounds | 1 | 2016 | 665 | 0.440 |
Why?
|
DNA Repair Enzymes | 1 | 2014 | 349 | 0.420 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2020 | 9185 | 0.420 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2020 | 1509 | 0.420 |
Why?
|
Drug Synergism | 2 | 2018 | 1791 | 0.410 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5867 | 0.390 |
Why?
|
Gallium Isotopes | 3 | 2021 | 7 | 0.390 |
Why?
|
ras Proteins | 1 | 2015 | 1060 | 0.360 |
Why?
|
Mutation | 7 | 2022 | 29717 | 0.320 |
Why?
|
Protein Kinases | 1 | 2015 | 1638 | 0.310 |
Why?
|
Computational Biology | 1 | 2020 | 3518 | 0.300 |
Why?
|
Kallikreins | 2 | 2020 | 258 | 0.300 |
Why?
|
Tissue Distribution | 3 | 2021 | 2335 | 0.290 |
Why?
|
Enzyme Inhibitors | 2 | 2015 | 3800 | 0.290 |
Why?
|
Antineoplastic Agents | 5 | 2018 | 13655 | 0.280 |
Why?
|
Prostate-Specific Antigen | 4 | 2021 | 2458 | 0.280 |
Why?
|
Radiopharmaceuticals | 4 | 2023 | 2658 | 0.260 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 250 | 0.250 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2906 | 0.250 |
Why?
|
Proteins | 1 | 2020 | 6096 | 0.250 |
Why?
|
Signal Transduction | 6 | 2020 | 23387 | 0.240 |
Why?
|
Kidney | 1 | 2019 | 7167 | 0.230 |
Why?
|
Ligands | 3 | 2019 | 3293 | 0.230 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4553 | 0.220 |
Why?
|
Colonic Neoplasms | 1 | 2014 | 2542 | 0.210 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6347 | 0.200 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2018 | 384 | 0.190 |
Why?
|
Nuclear Medicine | 1 | 2023 | 233 | 0.190 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2020 | 29 | 0.190 |
Why?
|
Apoptosis | 3 | 2016 | 9715 | 0.190 |
Why?
|
Receptor, EphA2 | 1 | 2020 | 42 | 0.180 |
Why?
|
Nuclear Proteins | 2 | 2017 | 5851 | 0.180 |
Why?
|
Neurofibromin 1 | 1 | 2020 | 196 | 0.170 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 1683 | 0.170 |
Why?
|
Genomics | 2 | 2021 | 5692 | 0.170 |
Why?
|
Lung Neoplasms | 6 | 2020 | 13019 | 0.160 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2022 | 794 | 0.160 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2020 | 2028 | 0.160 |
Why?
|
Gene Fusion | 1 | 2021 | 371 | 0.160 |
Why?
|
Isotope Labeling | 1 | 2019 | 414 | 0.150 |
Why?
|
Whole Body Imaging | 1 | 2019 | 280 | 0.150 |
Why?
|
GTP Phosphohydrolases | 1 | 2020 | 508 | 0.150 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2020 | 544 | 0.150 |
Why?
|
Cell Line, Tumor | 8 | 2021 | 16665 | 0.150 |
Why?
|
DNA Damage | 3 | 2016 | 2423 | 0.140 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 9639 | 0.140 |
Why?
|
Serine | 1 | 2020 | 828 | 0.140 |
Why?
|
Propranolol | 1 | 2018 | 502 | 0.140 |
Why?
|
Oncogenes | 1 | 2022 | 1263 | 0.140 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 5171 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 552 | 0.130 |
Why?
|
Parkinsonian Disorders | 1 | 2018 | 272 | 0.130 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2723 | 0.120 |
Why?
|
Humans | 31 | 2023 | 742088 | 0.120 |
Why?
|
Germany | 1 | 2016 | 860 | 0.120 |
Why?
|
Cysteine Endopeptidases | 1 | 2016 | 563 | 0.120 |
Why?
|
Positron-Emission Tomography | 3 | 2021 | 6259 | 0.110 |
Why?
|
DNA Mutational Analysis | 1 | 2022 | 4187 | 0.110 |
Why?
|
Cell Survival | 2 | 2021 | 5872 | 0.110 |
Why?
|
Cluster Analysis | 1 | 2020 | 2713 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1350 | 0.110 |
Why?
|
Neoplasms, Experimental | 2 | 2018 | 1274 | 0.110 |
Why?
|
Male | 14 | 2022 | 349538 | 0.110 |
Why?
|
Zirconium | 2 | 2023 | 100 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 1239 | 0.100 |
Why?
|
Melanoma | 2 | 2020 | 5462 | 0.100 |
Why?
|
Neoplasm Transplantation | 1 | 2015 | 2085 | 0.100 |
Why?
|
Radioisotopes | 2 | 2023 | 499 | 0.100 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1327 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5522 | 0.090 |
Why?
|
Recurrence | 2 | 2019 | 8333 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2015 | 3557 | 0.090 |
Why?
|
Gene Amplification | 1 | 2013 | 1062 | 0.080 |
Why?
|
Thyroid Neoplasms | 1 | 2022 | 2274 | 0.080 |
Why?
|
Drug Design | 1 | 2014 | 1078 | 0.080 |
Why?
|
RNA-Binding Proteins | 1 | 2018 | 1899 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2022 | 8425 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 1 | 2018 | 2038 | 0.080 |
Why?
|
Mice | 9 | 2021 | 81045 | 0.080 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 6313 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3502 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2016 | 19862 | 0.070 |
Why?
|
Animals | 11 | 2021 | 168561 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2948 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11001 | 0.070 |
Why?
|
Bayes Theorem | 1 | 2013 | 2303 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4823 | 0.070 |
Why?
|
Genome | 1 | 2013 | 1803 | 0.060 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 1940 | 0.060 |
Why?
|
Aged | 5 | 2020 | 162944 | 0.060 |
Why?
|
Skin Neoplasms | 2 | 2020 | 5662 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7873 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2940 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18006 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4801 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14720 | 0.050 |
Why?
|
Platinum | 1 | 2022 | 232 | 0.050 |
Why?
|
Quinolines | 2 | 2018 | 719 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4420 | 0.050 |
Why?
|
Prevalence | 1 | 2016 | 15194 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 799 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4839 | 0.040 |
Why?
|
Open Reading Frames | 1 | 2022 | 810 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 7901 | 0.040 |
Why?
|
Middle Aged | 4 | 2019 | 213127 | 0.040 |
Why?
|
Cyclin T | 1 | 2017 | 20 | 0.040 |
Why?
|
Naphthalenes | 1 | 2018 | 194 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2017 | 66 | 0.040 |
Why?
|
Azoxymethane | 1 | 2016 | 36 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2020 | 678 | 0.040 |
Why?
|
Cohort Studies | 1 | 2019 | 40450 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2021 | 77098 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2018 | 526 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2018 | 9735 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2019 | 1284 | 0.030 |
Why?
|
Intestinal Neoplasms | 1 | 2016 | 319 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1875 | 0.030 |
Why?
|
RNA Polymerase II | 1 | 2017 | 550 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2018 | 713 | 0.030 |
Why?
|
Prostate | 1 | 2021 | 1764 | 0.030 |
Why?
|
Diamines | 1 | 2012 | 59 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1038 | 0.030 |
Why?
|
Genes, myc | 1 | 2013 | 399 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2020 | 3612 | 0.030 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2013 | 462 | 0.030 |
Why?
|
Ubiquitination | 1 | 2016 | 1011 | 0.030 |
Why?
|
Quinazolines | 1 | 2018 | 1355 | 0.030 |
Why?
|
Organic Chemicals | 1 | 2012 | 211 | 0.030 |
Why?
|
Drug Utilization | 1 | 2018 | 1181 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2012 | 247 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 944 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2018 | 20774 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2013 | 732 | 0.020 |
Why?
|
Piperidines | 1 | 2018 | 1602 | 0.020 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2016 | 849 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 72145 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1683 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3689 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2017 | 4200 | 0.020 |
Why?
|
DNA Primers | 1 | 2012 | 2892 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3564 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2018 | 2633 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4929 | 0.020 |
Why?
|
Caenorhabditis elegans | 1 | 2016 | 1416 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17400 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2012 | 987 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11363 | 0.020 |
Why?
|
Pyrimidines | 1 | 2018 | 2933 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2017 | 3444 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6891 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4751 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10248 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5163 | 0.020 |
Why?
|
Female | 5 | 2022 | 379592 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7721 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10943 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 57683 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 5975 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7790 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10163 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 21821 | 0.010 |
Why?
|
Liver | 1 | 2015 | 7470 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 15994 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2013 | 4029 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 12164 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11472 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39004 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9410 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53187 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2013 | 62966 | 0.000 |
Why?
|